State Street
KLRS

State Street’s Kalaris Therapeutics KLRS Stock Holding History

State Street’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$153K Buy
26,510
+1,100
+4% +$9.76K ﹤0.01% 3953
2025
Q4 		$214K Buy
25,410
+2,800
+12% +$17.9K ﹤0.01% 3885
2025
Q3 		$131K Buy
22,610
+11,900
+111% +$39.3K ﹤0.01% 4003
2025
Q2 		$28.6K Hold
10,710
– – ﹤0.01% 4168
2025
Q1 		$86K Sell
10,710
-5
-0% -$49 ﹤0.01% 4000
2024
Q4 		$104K Buy
10,715
+1,044
+11% +$15.8K ﹤0.01% 3980
2024
Q3 		$180K Hold
9,671
– – ﹤0.01% 3844
2024
Q2 		$161K Sell
9,671
-41,558
-81% -$734K ﹤0.01% 3876
2024
Q1 		$889K Buy
51,229
+4,224
+9% +$68.9K ﹤0.01% 3500
2023
Q4 		$735K Sell
47,005
-473
-1% -$18.7K ﹤0.01% 3549
2023
Q3 		$2.35M Buy
47,478
+6,871
+17% +$468K ﹤0.01% 3262
2023
Q2 		$3.18M Buy
40,607
+2,102
+5% +$200K ﹤0.01% 3207
2023
Q1 		$3.49M Buy
38,505
+248
+0.6% +$31.6K ﹤0.01% 3125
2022
Q4 		$4.51M Buy
38,257
+105
+0.3% +$17.8K ﹤0.01% 3077
2022
Q3 		$6.92M Buy
38,152
+6,839
+22% +$1.07M ﹤0.01% 2896
2022
Q2 		$2.81M Buy
31,313
+6,305
+25% +$661K ﹤0.01% 3365
2022
Q1 		$3.88M Sell
25,008
-28,170
-53% -$5.62M ﹤0.01% 3303
2021
Q4 		$15.8M Buy
53,178
+316
+0.6% +$147K ﹤0.01% 2636
2021
Q3 		$30.5M Sell
52,862
-21,554
-29% -$9.98M ﹤0.01% 2169
2021
Q2 		$33.8M Buy
74,416
+6,401
+9% +$3.3M ﹤0.01% 2132
2021
Q1 		$36.6M Buy
68,015
+35,202
+107% +$29.6M ﹤0.01% 1968
2020
Q4 		$29M Buy
32,813
+21,941
+202% +$16.9M ﹤0.01% 2006
2020
Q3 		$6.88M Buy
+10,872
New +$7.42M ﹤0.01% 2643

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

State Street's KLRS Position: Q1 2026 in Review

State Street increased its Kalaris Therapeutics (KLRS) stake by 4.3% in Q1 2026, buying an estimated $9.76K and bringing the position to 26,510 shares worth $153K. The position accounts for ﹤0.01% of the portfolio, ranked #3953.

State Street first reported a position in KLRS in Q3 2020 and has held it in 23 quarters since. The position peaked at $36.6M in Q1 2021. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • State Street held 26,510 shares of Kalaris Therapeutics worth $153K as of Q1 2026.
  • State Street bought 1,100 Kalaris Therapeutics shares in Q1 2026, an estimated $9.76K.
  • Kalaris Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3953 holding.
  • State Street first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • State Street's Kalaris Therapeutics position peaked at $36.6M in Q1 2021.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.